Furthermore, Anti-CD47 antibody therapy disrupts the signal on CD34+CD38- leukemic stem cells, enhancing macrophage-mediated phagocytosis and achieving durable remissions in preclinical Acute Myeloid Leukemia (AML) models (92, 93). The gene discussed is CD34; the disease is acute myeloid leukemia.